Haemophilia is a rare bleeding disorder affecting less than 0.01 per cent of Malaysians, requiring daily medical care and ...

Be Biopharma has raised $82m in financing to advance a gene therapy targeting hemophilia B to a Phase I/II trial, whilst also adding an ex-Roche exec who was involved with the launch of a haemophilia ...

Haemophilia is a rare genetic bleeding disorder that causes the blood to take a long time to clot because of a deficiency in one or several blood clotting factors. It is almost exclusively found ...

British doctors say they have achieved "mind-blowing" results in an attempt to rid people of haemophilia A. Patients are born with a genetic defect that means they do not produce a protein needed ...

There are two main types of hemophilia - Hemophilia A (due to factor VIII deficiency) and Hemophilia B (due to factor IX deficiency). They are clinically almost identical and are associated with ...

Clotting proteins missing or are defective in hemophilia can directly affect the activity of cells responsible for bone ...

The EMA's human medicines advisory committee has recommended that BioMarin Pharmaceutical's haemophilia A gene therapy Roctavian be approved in the EU, removing one of the last barriers to launch.

The experts say advances like this could revolutionise the lives of adults with haemophilia in the next few years. From the day Elliott was born, he was unable to make enough of a crucial protein ...

UK High Court judge unconvinced by Pfizer that uniQure’s patent is invalid | Companies in dispute over patents covering ...

The increased RM25 million allocation in the 2025 Budget for rare disease treatment costs is expected to improve haemophilia ...

The company’s MI Cancer Seek is approved as a companion diagnostic for multiple cancer therapies, including MSD’s Keytruda, ...

FRANKFURT (Reuters) -Roche's third-quarter sales gained a currency-adjusted 9%, beating market expectations, on higher ...